Dupilumab: One therapy to treat multiple atopic diseases

Abstract

Dupilumab is a fully humanized monoclonal antibody targeting the interleukin (IL)-4Rα subunit of the IL-4 and IL-13 receptors. IL-4 and IL-13 are type 2 cytokines involved in the pathogenesis of atopic dermatitis (AD) and allergic diseases including asthma, food allergy, allergic rhinitis (AR), eosinophilic esophagitis (EoE), and chronic rhinosinusitis with nasal polyposis (CRwNP). Therefore, dupilumab has been hypothesized as a potential treatment for all of these atopic conditions,1-3 but is currently only approved by the US Food and Drug Administration for patients 6 years and older with moderate-to-severe AD, 12 years and older with moderate-to-severe asthma, and adults with CRwNP.

Topics & Concepts